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Streptococcus pyogenes infections cause over 517,000 deaths per year.  Treatments 
typically fail to eradicate S. pyogenes bacteria, resulting in recurrent infections. Therefore, we 
are investigating the effects of rifampin and ML141 co-treatment on S. pyogenes intracellular 
infections and toxicity of these treatments in RAW 264.7 cells. Rifampin is an antibiotic, 
whereas ML141 is a molecule that inhibits S. pyogenes invasion. Our experiments will be 
conducted by infecting RAW 264.7 cells with S. pyogenes bacteria and treating them with 
rifampin alone, ML141 alone, or rifampin with ML141 co-treatment. Also, cytotoxicity assays 
will be performed on rifampin and ML141 co-treatment, rifampin alone, and ML141 alone, using 
a flow cytometer.  It is our hypothesis that rifampin and ML141 co-treatment will have the 
lowest S. pyogenes bacterial count. We also hypothesize rifampin and ML141 co-treatment will 
not be toxic. If both hypothesis are supported by the data S. pyogenes recurrent intracellular 
infections will be decreased. Furthermore, rifampin and ML141 co-treatment could be used as a 
better therapeutic approach for S. pyogenes recurrent infections.  
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Introduction 
Streptococcus pyogenes (Group A) is a bacterium that can cause a wide variety of diseases in 
humans of all ages; however, children under the age of 15 are most likely to be infected [1]. 
Unfortunately, there is a lack of treatment for patients with recurrent S. pyogenes infections, 
resulting in failure rates as high as 100% [2]. S. pyogenes can form biofilms, which could be the 
explanation for treatment failures and reoccurrences of these bacterial infections [3]. Group A 
Streptococcus also avoids antibiotic treatments by hiding intracellularly in phagocytic cells [4]. 
Both hypotheses could be the reason for recurrent S. pyogenes infections. Although our approach 
does not target biofilms, it does focus on intracellular infection. Our lab believes that by 
targeting S. pyogenes intracellular infections therapeutically, reoccurring infections could be 
prevented. 
 ML141 helps limit the intracellular infection of S. pyogenes bacteria, but does not get rid 
of all the bacteria within the host cell (unpublished). Rifampin is a bactericidal antibiotic and 
works well in treating intracellular infection but is also cytotoxic when used in high 
concentrations [5]. Therefore, it is proposed that rifampin and ML141 used as a co-treatment 
could decrease S. pyogenes bacteria. We hypothesize that the amount of rifampin needed to clear 
infection of S. pyogenes within the host cell could be decreased with the co-treatment of ML141, 
and therefore decrease toxicity. Rifampin and ML141 co-treatment could potentially stop 
recurrent infections.  
The focus of this thesis proposal is to examine this hypothesis. The experimental design 
is to count colonies on blood agar plates to detect what concentration of rifampin and ML141 co-
treatment results in the greatest decrease in S.pyogenes intracellular bacteria. 
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Materials & Methods 
Chemicals. In the investigation on inhibiting S.pyogenes intracellular infections, the following 
were used at the appropriate concentration and duration provided in figure1 and methods below: 
THB- Todd Hewitt Broth, dimethyl sulfoxide- DMSO, sterile water, agar plates, 0.85% saline 
(Thermo-Fisher Scientific Waltham, MA), RAW 264.7 cells (American Type Culture Collection, 
ATCC, Manassas, VA), rifampin (MP Biomedicals, Santa Ana, CA), ML141 (Dr. Sammelson, 
Department of Chemistry, Ball State University), rifampin and ML141 co-treatment, gentamicin 
(Sigma Aldrich, St. Louis, MO), and sheep-blood (Cleveland Scientific, Cleveland, OH). 
RAW Cell Culture. S. pyogenes were cultured (200 rpm, 37℃, 24 hr) in Todd Hewitt Broth 
(Fisher, #DF0492-17-6) and subcultured before doing the assay.  
Invasion Assay. To begin the assay, bacteria were spun (10000 rpm, 37℃, 3 min) and washed. 
The appropriate concentration of bacteria (1.92 x 106 CFU/ml) mixture was transferred into 
dishes containing RAW 264.7 cells (6 x 105) and incubated (37℃, 5% CO2, 30 min). Each 
culture dish was washed and treated with dimethyl sulfoxide (DMSO,0.1%), rifampin (5 mg/L), 
ML141 (10 µM), and rifampin and ML141 co-treatment (5 mg/L, 10 µM), and incubated (37℃, 
5% CO2, 1hr). Following the treatment, plates were washed and treated with gentamicin (500 
µg/ml,) and incubated (37℃, 5% CO2, 30 min). Next, plates were washed 3 times. RAW 264.7 
cells were lysed by incubation in chilled sterile water (5 min,). After incubation, each dish was 
washed forcefully with solution in the dish, and plated onto blood agar plates (37℃, 5% CO2, 24 
hr). The following day, colony counts were used to quantify colony forming units (CFU)/ml. 
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Statistical Analyses. Data from the invasion assay were collected and analyzed using one-way 
analysis of variance (ANOVA) followed by Tukey’s multiple comparison, where P <0.05 is 
considered significant. 
Results 
Rifampin and ML141 co-treatment decreases S. pyogenes intracellular infection more than 
ML141 alone. However, there was no significant difference in rifampin alone compared to 
rifampin and ML141. Therefore, we hypothesize decreasing the concentration of rifampin will 
result in rifampin and ML141 having a significant difference in comparison to rifampin alone.  
 
Figure. 1. Rifampin and co-treatment ML141 decreases S. pyogenes intracellular bacterial 
infection. S. pyogenes were cultured (200 rpm, 37℃, 24 hr) in Todd Hewitt Broth and 
subcultured before doing the assay. To begin the assay, bacteria were pelleted (10000 rpm, 37℃, 
3 min) and washed. The appropriate concentration of bacteria (1.92 x 106 CFU/ml) was 
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transferred into dishes containing RAW 264.7 cells (6 x 105) and incubated (37℃, 5% CO2, 30 
min). RAW cells were treated with dimethyl sulfoxide (DMSO), rifampin (5 mg/L), ML141 (10 
µM), and rifampin and ML141 co-treatment (5 mg/L, 10 µM) and incubated (37℃, 5% CO2, 
1hr). Following treatment, plates were washed and treated with gentamicin (500 µg/ml), and 
incubated (37℃, 5% CO2, 30 min). Following extensive washing, RAW 264.7 cells were lysed 
by incubation in chilled sterile water (5 min). After incubation, each dish was washed forcefully 
with solution in the dish, and serial dilutions were plated onto Sheep Blood Agar plates (37℃, 
5% CO2, 24 hr). Colony forming units (CFU)/ml were quantified. One-way ANOVA followed 
by Tukey’s multiple comparison was performed to test for significance, where P <0.05 is 
significant (*less than DMSO control, ** less than ML141 alone). 
Discussion:  
This study consisted of an investigation on the effects of rifampin and ML141 co-treatment on S. 
pyogenes infections in RAW cells. Results indicated that rifampin and ML141 co-treatment 
decreases S. pyogenes intracellular infection more than ML141 alone (figure 1). However, there 
was no significant difference in rifampin alone compared to rifampin and ML141 (figure 1). 
ML141 decreases intracellular infection by Streptococcus pyogenes (unpublished). Rifampin also 
decreases intracellular infection by S. pyogenes (figure1).The problem is that rifampin and 
ML141 alone do not get rid of all the infection caused by S. pyogenes in the cell, and both are 
toxic to cells when used in high concentrations [1, 2]. As indicated in figure 1, rifampin and 
ML141 co-treatment had a greater decrease in S. pyogenes bacterial colony counts compared to 
ML141 alone and rifampin alone. This suggests S. pyogenes recurrent infections to be less likely 
to occur in patients treated with rifampin and ML141 co-treatment. Further research using 
different concentrations of rifampin with ML141 co-treatment will have to be investigated to 
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determine if a lower dosage of rifampin would be effective in decreasing S.pyogenes intracellular 
bacteria. Furthermore, rifampin and ML141 co-treatment inhibiting S. pyogenes intracellular 
infections will lead to a better understanding of S. pyogenes recurrent infections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
References 
1. Shen, Y., et al., Identification and Characterization of Fluoroquinolone Non-susceptible 
Streptococcus pyogenes Clones Harboring Tetracycline and Macrolide Resistance in Shanghai, 
China. Front Microbiol, 2018. 9: p. 542. 
2. Camara, M., A. Dieng, and C.S. Boye, Antibiotic susceptibility of streptococcus pyogenes isolated 
from respiratory tract infections in dakar, senegal. Microbiol Insights, 2013. 6: p. 71-5. 
3. Hirota, K., et al., Fosfomycin reduces CD15s-related antigen expression of Streptococcus 
pyogenes. Antimicrob Agents Chemother, 1998. 42(5): p. 1083-7. 
4. Thulin, P., et al., Viable group A streptococci in macrophages during acute soft tissue infection. 
PLoS Med, 2006. 3(3): p. e53. 
5. Hoger, P.H., et al., Uptake, intracellular activity, and influence of rifampin on normal function of 
polymorphonuclear leukocytes. Antimicrob Agents Chemother, 1985. 28(5): p. 667-74. 
6.           Cordero, D., et al., Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus 
aureus. Curr Pharm Biotechnol, 2014. 15(8): p. 727-37. 
 
 
 
